Merck/Intervet/Schering-Plough Animal Health is a global, research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services. We offer one of the industry’s most innovative portfolios, spanning products for the prevention, treatment and control of disease in all major farm and companion animal species.
Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.
Merck's animal health division, formerly known as Intervet/Schering-Plough Animal Health, announced that it has adopted the name of its parent company and will now be called Merck Animal Health.
It is the world leader in pharmaceuticals and vaccines for aquaculture and major products in its portfolio are the antibiotic AQUAFLOR (florfenicol), the parasiticide SLICE (emamectin benzoate) and the vaccine ranges AQUAVAC and NORVAX. The company is based in Boxmeer, The Netherlands.
We are a highly proactive, robust and diversified company with a strong, scientifically-proven, product portfolio and an ever-growing global reach.
With offices in more than 50 countries, we successfully market our products in over 140 countries and operate a network of manufacturing sites and research and development (R&D) facilities around the world.
With offices in more than 50 countries, we successfully market our products in over 140 countries and operate a network of manufacturing sites and research and development (R&D) facilities around the world.
Thai Union records 1Q24 net profit of USD 32.49 M Thailand
Net profit increased 53.9 percent from 1Q23 adjusted net profit to THB 1.2 billion (USD 32.49 M) due to a healthier operating profit
Gross profit margin improved to 17.3 percent, with stron...